Me faces potential bankruptcy, raising concerns about the security of the genetic data of its 15 million customers and the ...

Me continues to face challenges in maintaining its revenue and captures growth. Click here to read why ME stock is a Sell.

Me (ME), the company that popularized consumer genetic testing, is facing significant financial and leadership challenges as ...

Over the past year, 23andMe set new corporate governance lows. CEO Anne Wojcicki now enters de facto “founder mode” after a ...

Biotech company 23andMe was once hailed as one of the most successful businesses selling DNA analysis services to anybody who ...

Financial and security chaos at the once-pioneering genetic testing firm has intensified concerns about user data. Here's how ...

In 2023, 23andMe had a data breach the exposed millions of people ancestry data. The lawsuit that followed, has reached a $30 ...

A giant biotechnology company might be about to go bust. What will happen to the millions of people’s DNA it holds?

Once worth $6 billion, 23andMe has lost 98% of its value and is on the verge of being delisted from the Nasdaq. So what ...

The implications of this sale are significant, raising concerns over data privacy and the potential misuse of sensitive ...

A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...

For the last decade, 23andMe has been known worldwide for offering genetic testing, ancestry tracing and health information ...